Abstract
Traditionally, syndromes have been named after the physician who originally identified the condition. These are referred to as eponymous syndromes. Nevertheless, the term eponym is to be regarded in a broader sense, since - by definition - an eponym is a person, place, or thing after whom or which something is named. Accordingly, some eponymous syndromes do not refer to the physician who originally reported the condition, but alternatively to the indicator patient, a geographic location, or a historical, literary, or mythological context. The recent past has seen a shift towards naming conditions descriptively by symptoms rather than eponymously. When the syndrome name is formed as an abbreviation from the initial letters of the symptoms, it is referred to as an acronym. The use of acronyms has become particularly popular and is often taught as mnemonic device or used as mental checklist. However, the use of eponyms confers historical, literary, and cultural information that reaches beyond and therefore conveys the dignity of a broader educational background and understanding.
References
1.
Goodman LE: Islamic Humanism. Oxford University Press, 2003, p 155.
2.
Patel CB, Rashid RM: Averting the proliferation of acronymophilia in dermatology: effectively avoiding ADCOMSUBORDCOMPHIBSPAC. J Am Acad Dermatol 2009;60:340-344.
3.
Markovic M, Ivanović B, Bjekić M, Sipetic S: Are dermatologists familiar with acronyms? Indian J Dermatol Venereol Leprol 2013;79:849.
4.
Molho-Pessach V, Agha Z, Aamar S, Glaser B, Doviner V, Hiller N, Zangen DH, Raas-Rothschild A, Ben-Neriah Z, Shweiki S, Elpeleg O, Zlotogorski A: The H syndrome: a genodermatosis characterized by indurated, hyperpigmented, and hypertrichotic skin with systemic manifestations. J Am Acad Dermatol 2008;59:79-85.
5.
Wren JD, Garner HR: Heuristics for identification of acronym-definition patterns within text: towards an automated construction of comprehensive acronym-definition dictionaries. Methods Inf Med 2002;41:426-434.
6.
Grosshans EM: SAPHO: the impossible acronym. Dermatology 1993;186:161-162.
7.
Trüeb RM: A comment on frontal fibrosing alopecia (Axel Munthe's syndrome). Int J Trichology 2016;8:203-205.
8.
Chen W, Ring J, Happle R: Congenital generalized hypertrichosis terminalis: a proposed classification and a plea to avoid the ambiguous term “Ambras syndrome.” Eur J Dermatol 2015;25:223-227.
9.
Kossard S: Postmenopausal frontal fibrosing alopecia. Scarring alopecia in a pattern distribution. Arch Dermatol 1994;130:770-774.
10.
Fernandez-Flores A: Frontal pseudoalopecia in history: part 1 - fashionable forms. Clin Dermatol 2012;30:548-552.
11.
Fernandez-Flores A: Frontal pseudoalopecia in history: part 2 - cultural forms. Clin Dermatol 2013;31:131-134.
12.
Serrano-Falcón C, Serrano-Ortega S: Did the Duchess of Urbino have frontal fibrosing alopecia? Actas Dermosifiliogr 2008;99:737-738.
13.
Axel Munthe. The Story of San Michele. Chapter XIII (Mamsell Agata), p 157. London, John Murray Publishers Ltd., 2004.
14.
Baumeister FA, Egger J, Schildhauer MT, Stengel-Rutkowski S: Ambras syndrome: delineation of a unique hypertrichosis universalis congenita and association with a balanced pericentric inversion (8) (p11.2; q22). Clin Genet 1993;44:121-128.
15.
Navarini AA, Nobbe S, Trüeb RM: Marie Antoinette syndrome. Arch Dermatol 2009;145:656.
16.
Trüeb RM, Navarini AA: Thomas More syndrome. Dermatology 2010;220:55-56.
17.
Navarini AA, Trüeb R: Why Henry III of Navarre's hair probably did not turn white overnight. Int J Trichology 2010;2:2-4.
18.
Mühlbauer W, Holm C, Wood DL: The Thersites complex in plastic surgical patients. Plast Reconstr Surg 2001;107:319-326.
19.
Brosig B, Kupfer J, Niemeier V, Gieler U: The “Dorian Gray Syndrome:” psychodynamic need for hair growth restorers and other “fountains of youth”. Int J Clin Pharmacol Ther 2001;39:279-283.
20.
Wilde O: The Picture of Dorian Gray. London, Penguin Popular Classics (1994), 1891.
21.
Asher R: Munchausen's syndrome. Lancet 1951;1:339-341.
22.
Vaughan ED Jr, Sawyers JL, Scott HW Jr: The Rapunzel syndrome. An unusual complication of intestinal bezoar. Surgery 1968;63:339-343.
23.
Drolet BA: Cutaneous signs of neural tube dysraphism. Pediatr Clin North Am 2000;47:813-823.
24.
Trüeb RM: Causes and management of hypertrichosis. Am J Clin Dermatol 2002;3:617-627.
25.
Cockayne EA: Gargoylism (chondro-osteo-dystrophy, hepatosplenomegaly, deafness) in two brothers. Proc R Soc Med 1936;30:104-107.
26.
Clairevaux B St. Apologia ad Guillelmum abbatem. In: Leclercq J, Rochais HM: Tractatus et Opuscula. S. Bernardi Opera. 3. Rome, Editiones cistercienses, 1963
27.
Hughes HE, Davies SJ: Coarctation of the aorta in Kabuki syndrome. Arch Dis Child. 1994;70:512-514.
28.
Burke LW, Jones MC: Kabuki syndrome: underdiagnosed recognizable pattern in cleft palate patients. Cleft Palate Craniofac J 1995;32:77-84.
29.
Classification and nomenclature of morphological defects. Lancet 1975;1:513.
30.
Macaskill MR, Anderson TJ: Whose name is it anyway? Varying patterns of possessive usage in eponymous neurodegenerative diseases. Peer J 2013;1:e67.
31.
Jana N, Barik S, Arora N: Current use of medical eponyms - a need for global uniformity in scientific publications. BMC Med Res Methodol 2009;9:18.
33.
Goodrick S: What's in an eponym? Lancet Neurol 2014;13:31.
34.
Chatard H: Graham-Little and Lassueur syndrome. Bull Soc Fr Dermatol Syphiligr 1972;79:194.
35.
Zouboulis CC, Grzybowski A: The upright name of the disorder: Adamantiades-Behçet's disease. Med Sci Monit 2010;16:LE19-LE20.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
